Evidence map›Paper›PMID 35545318›Full record

ArticleJournal for immunotherapy of cancer2022

Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma.

Gino Kim In, Aparna Nallagangula, Jacob Seung Choi, Lisa Tachiki, Matthew J Blackburn, Stephen Capone, Kathryn B Bollin, Daniel Y Reuben, Keisuke Shirai, Sandy Zhang-Nunes and 8 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 1 country.

Gino Kim InDivision of Oncology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, USA gino.in@med.usc.edu.ORCID 0000-0002-7060-5123
Aparna NallagangulaDivision of Medical Oncology, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
Jacob Seung ChoiDivision of Hematology and Oncology, Northwestern University, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, USA.
Lisa TachikiDivision of Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Matthew J BlackburnDivision of Hematology and Oncology, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA.
Stephen CaponeDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-7231-1535
Kathryn B BollinDivision of Hematology/Oncology, Scripps Clinic, Scripps MD Anderson Cancer Center, San Diego, California, USA.
Daniel Y ReubenDivision of Hematology & Oncology, Medical University of South Carolina, Hollings Cancer Center, Charleston, South Carolina, USA.
Keisuke ShiraiSection of Hematology/Oncology, Dartmouth University, Norris Cotton Cancer Center, Lebanon, New Hampshire, USA.
Sandy Zhang-NunesDepartment of Ophthalmology, University of Southern California, Keck School of Medicine, Los Angeles, California, USA.
Omar RagabDepartment of Radiation Oncology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Alicia TerandoSection of Surgical Oncology, University of Southern California, Keck School of Medicine, Los Angeles, California, USA.
Jenny C HuDepartment of Dermatology, University of Southern California, Keck School of Medicine, Los Angeles, California, USA.
Han LeeDepartment of Dermatology, University of Southern California, Keck School of Medicine, Los Angeles, California, USA.
Shailender BhatiaDivision of Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.ORCID 0000-0002-3816-2238
Sunandana ChandraDivision of Hematology and Oncology, Northwestern University, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, USA.
Jose LutzkyDivision of Medical Oncology, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, USA.ORCID 0000-0002-9503-2130
Geoffrey Thomas GibneyDivision of Hematology and Oncology, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA.ORCID 0000-0002-5401-8498
University of Southern California · USGeorgetown University · USNorthwestern University · USUniversity of Miami · USUniversity of Washington · USDartmouth College · USMedical University of South Carolina · USScripps Clinic · USThe University of Texas MD Anderson Cancer Center · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
Southern California Clinical and Translational Science InstituteUL1TR001855 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Thomas A Buchanan, Michele D. Kipke · 2016 to 2026
$81.3M
NCATS NIH HHS UL1 TR001855NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

backgroundBasal cell carcinoma (BCC) is the most common malignancy worldwide, yet the management of patients with advanced or metastatic disease is challenging, with limited treatment options. Recently, programmed death receptor 1 (PD-1) inhibition has demonstrated activity in BCC after prior Hedgehog inhibitor treatment.

methodsWe conducted a multicenter, retrospective analysis of BCC patients treated with PD-1 inhibitor therapy. We examined the efficacy and safety of PD-1 therapy, as well as clinical and pathological variables in association with outcomes. Progression-free survival (PFS), overall survival (OS) and duration of response (DOR) were calculated using Kaplan-Meier methodology. Toxicity was graded per Common Terminology Criteria for Adverse Events V.5.0.

resultsA total of 29 patients with BCC who were treated with PD-1 inhibition were included for analysis, including 20 (69.0%) with locally advanced and 9 (31.0%) with metastatic disease. The objective response rate was 31.0%, with five partial responses (17.2%), and four complete responses (13.8%). Nine patients had stable disease (31.0%), with a disease control rate of 62.1%. The median DOR was not reached. Median PFS was 12.2 months (95% CI 0.0 to 27.4). Median OS was 32.4 months (95% CI 18.1 to 46.7). Two patients (6.9%) developed grade 3 or higher toxicity, while four patients (13.8%) discontinued PD-1 inhibition because of toxicity. Higher platelets (p=0.022) and any grade toxicity (p=0.024) were significantly associated with disease control rate.

conclusionsThe clinical efficacy of PD-1 inhibition among patients with advanced or metastatic BCC in this real-world cohort were comparable to published trial data. Further investigation of PD-1 inhibition is needed to define its optimal role for patients with this disease.

Indexed as

Basal Cell CarcinomaSkin NeoplasmsHedgehog ProteinsHumansProgrammed Cell Death 1 ReceptorRetrospective StudiesHedgehog ProteinsProgrammed Cell Death 1 Receptorimmunotherapyprogrammed cell death 1 receptorskin neoplasms

Identifiers

PMID35545318
PMCPMC9096532
OpenAlexW4280493379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.